
Sanofi’s investigational multiple sclerosis drug Lemtrada has beaten Rebif in a late-stage trial. The Phase III results show that 78% …

Genzyme’s multiple sclerosis candidate Lemtrada has impressed in a new phase II head-to-head trial. Five years’ worth of mid-stage data …

Sanofi-Aventis has entered into a confidentiality agreement with Genzyme to discuss the prospects of Lemtrada, which suggests a deal could …

